RNA-based genetic therapies targeting MAPT mRNA in patients with AD may allow for a comprehensive amelioration of all forms of phosphorylated and aggregated tau, regardless of location, as they should reduce the production of all forms of tau protein. This evidence concerns the gene MAPT and Alzheimer disease.